Leerink Partners Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE)
Leerink Partners began coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) in a research report report published on Tuesday, MarketBeat reports. The brokerage issued an outperform rating and a $45.00 price target on the stock. Several other equities analysts also recently weighed in on SYRE. The Goldman Sachs Group raised Spyre Therapeutics to […]
Leerink Partners began coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) in a research report report published on Tuesday, MarketBeat reports. The brokerage issued an outperform rating and a $45.00 price target on the stock. Several other equities analysts also recently weighed in on SYRE. The Goldman Sachs Group raised Spyre Therapeutics to […]
